29.45
price up icon2.35%   0.675
 
loading
Tg Therapeutics Inc stock is traded at $29.45, with a volume of 2.18M. It is up +2.35% in the last 24 hours and down -21.21% over the past month. TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
See More
Previous Close:
$28.77
Open:
$28.74
24h Volume:
2.18M
Relative Volume:
1.11
Market Cap:
$4.67B
Revenue:
$264.79M
Net Income/Loss:
$-14.36M
P/E Ratio:
-267.68
EPS:
-0.11
Net Cash Flow:
$-28.11M
1W Performance:
+4.86%
1M Performance:
-21.21%
6M Performance:
-4.65%
1Y Performance:
+20.68%
1-Day Range:
Value
$28.50
$29.48
1-Week Range:
Value
$27.23
$29.48
52-Week Range:
Value
$21.11
$46.48

Tg Therapeutics Inc Stock (TGTX) Company Profile

Name
Name
Tg Therapeutics Inc
Name
Phone
(212) 554-4484
Name
Address
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Name
Employee
352
Name
Twitter
@TGTherapeutics
Name
Next Earnings Date
2025-03-03
Name
Latest SEC Filings
Name
TGTX's Discussions on Twitter

Compare TGTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TGTX
Tg Therapeutics Inc
29.45 4.40B 264.79M -14.36M -28.11M -0.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-10-25 Resumed Goldman Neutral
Oct-29-24 Initiated TD Cowen Buy
Aug-02-23 Upgrade Goldman Sell → Neutral
Jun-26-23 Resumed Jefferies Buy
May-20-22 Initiated BofA Securities Underperform
Feb-23-22 Reiterated B. Riley Securities Buy
Nov-15-21 Downgrade Goldman Neutral → Sell
Apr-20-21 Initiated Goldman Neutral
Apr-19-21 Reiterated H.C. Wainwright Buy
Sep-01-20 Initiated JP Morgan Overweight
Aug-11-20 Reiterated H.C. Wainwright Buy
Jun-05-20 Initiated Evercore ISI Outperform
Jan-17-20 Reiterated H.C. Wainwright Buy
Nov-27-19 Resumed B. Riley FBR Buy
Feb-06-19 Resumed Jefferies Buy
Sep-25-18 Downgrade Raymond James Strong Buy → Outperform
Mar-09-18 Reiterated B. Riley FBR, Inc. Buy
Dec-01-17 Resumed B. Riley FBR, Inc. Buy
Nov-14-17 Resumed H.C. Wainwright Buy
Apr-25-17 Initiated Jefferies Buy
Mar-06-17 Reiterated FBR & Co. Outperform
Oct-06-16 Resumed Brean Capital Buy
May-27-16 Initiated SunTrust Buy
Dec-01-15 Initiated FBR Capital Outperform
Sep-09-15 Initiated Raymond James Strong Buy
Aug-12-15 Resumed H.C. Wainwright Buy
Jun-19-15 Reiterated Brean Capital Buy
Dec-11-14 Reiterated ROTH Capital Buy
Dec-10-14 Reiterated ROTH Capital Buy
View All

Tg Therapeutics Inc Stock (TGTX) Latest News

pulisher
Aug 20, 2025

Will TG Therapeutics Inc. Reverse From Oversold ConditionsEarnings Growth Report & Fast Gain Stock Trading Tips - classian.co.kr

Aug 20, 2025
pulisher
Aug 19, 2025

TG Therapeutics: Looking For The Stimulus For A Turnaround (NASDAQ:TGTX) - Seeking Alpha

Aug 19, 2025
pulisher
Aug 17, 2025

Fibonacci Support Holding Strong in TG Therapeutics Inc.2025 Trading Recap & Advanced Swing Trade Entry Alerts - metal.it

Aug 17, 2025
pulisher
Aug 16, 2025

TG Therapeutics (NASDAQ:TGTX) Advances 5.1% This Week, Taking Three-year Gains to 302% - 富途牛牛

Aug 16, 2025
pulisher
Aug 15, 2025

Why TG Therapeutics Inc. stock attracts strong analyst attentionJobs Report & Capital Efficiency Focused Ideas - mustnews.co.kr

Aug 15, 2025
pulisher
Aug 15, 2025

TG Therapeutics falls after Q2 miss despite guidance raise - MSN

Aug 15, 2025
pulisher
Aug 15, 2025

TG Therapeutics' (NASDAQ:TGTX) Anemic Earnings Might Be Worse Than You Think - Yahoo Finance

Aug 15, 2025
pulisher
Aug 14, 2025

Is TG Therapeutics Inc. in a long term uptrendWeekly Profit Recap & Proven Capital Preservation Tips - thegnnews.com

Aug 14, 2025
pulisher
Aug 14, 2025

TG Therapeutics Inc. Sees Spike in Bullish Option FlowShort Setup & Reliable Momentum Entry Alerts - beatles.ru

Aug 14, 2025
pulisher
Aug 14, 2025

Intraday Charts Show Spike in TG Therapeutics Inc. ActivityWeekly Market Summary & Weekly Watchlist for Hot Stocks - thegnnews.com

Aug 14, 2025
pulisher
Aug 13, 2025

How Investors Are Reacting To TG Therapeutics (TGTX) Raising 2025 Revenue Guidance After Strong Q2 Results - simplywall.st

Aug 13, 2025
pulisher
Aug 12, 2025

SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire

Aug 12, 2025
pulisher
Aug 12, 2025

TG Therapeutics Faces Regulatory and Legal Challenges Amid AI Risks - AInvest

Aug 12, 2025
pulisher
Aug 11, 2025

Navigating AI Risks: TG Therapeutics Faces Regulatory and Legal Challenges - The Globe and Mail

Aug 11, 2025
pulisher
Aug 10, 2025

TG Therapeutics Faces Regulatory and Legal Risks with AI Integration - AInvest

Aug 10, 2025
pulisher
Aug 09, 2025

TG Therapeutics Boosts Financial Strength with New Securities Filing - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

TG Therapeutics Inc's Financial Performance and Strategic Positioning - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

Willdan Group's Price Target Raised by Wedbush to $120, Up 41.18% - AInvest

Aug 09, 2025
pulisher
Aug 09, 2025

Tg Therapeutics 2025 Q2 Earnings Net Income Surges 309.8% - AInvest

Aug 09, 2025
pulisher
Aug 08, 2025

TG Therapeutics: Strategic Capital Flexibility Fuels Briumvi's Global Expansion and R&D Momentum - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

TG THERAPEUTICS, INC. SEC 10-Q Report - TradingView

Aug 08, 2025
pulisher
Aug 08, 2025

TG Therapeutics raises BRIUMVI 2025 revenue guidance to $575M while advancing subcutaneous pipeline - MSN

Aug 08, 2025
pulisher
Aug 06, 2025

TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 06, 2025
pulisher
Aug 06, 2025

TR | OpenAI4o Maintains TG Therapeutics(TGTX.US) With Hold Rating, Cuts Target Price to $30 - 富途牛牛

Aug 06, 2025
pulisher
Aug 06, 2025

TGTX Stock Falls 14.1% Amid Market Volatility - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

TGTX Raises FY25 Revenue Projection, BRIUMVI Target Increased - AInvest

Aug 06, 2025
pulisher
Aug 05, 2025

TG Therapeutics’ Earnings Call Highlights BRIUMVI Success - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

TG Therapeutics Raises Outlook As BRIUMVI Sales Climb - Finimize

Aug 05, 2025
pulisher
Aug 05, 2025

Tg Therapeutics shares fall 1.06% after-hours as clinical trial updates and legal risks weigh on sentiment. - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

TGTX Down As Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - Barchart.com

Aug 05, 2025
pulisher
Aug 05, 2025

New Lantern Expands AI Radiology Platform with Mammography and PET/CT Viewers - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

TG Therapeutics (TGTX) Misses Q2 Earnings Estimates - MSN

Aug 05, 2025
pulisher
Aug 05, 2025

TG Therapeutics Second Quarter 2025 Earnings: Misses Expectations - simplywall.st

Aug 05, 2025
pulisher
Aug 05, 2025

TG Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat

Aug 05, 2025
pulisher
Aug 05, 2025

TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada

Aug 05, 2025
pulisher
Aug 05, 2025

TG Therapeutics Inc (TGTX) Q2 2025 Earnings Call Highlights: Rob - GuruFocus

Aug 05, 2025
pulisher
Aug 05, 2025

TG Therapeutics: Q2 Earnings Snapshot - Connecticut Post

Aug 05, 2025
pulisher
Aug 05, 2025

TG Therapeutics Boosts Revenue Forecast Amid Strong BRIUMVI Sales - TipRanks

Aug 05, 2025
pulisher
Aug 04, 2025

TG Therapeutics Stock Plunges 17.99% on Missed Earnings Despite Strong Revenue Surging Trading Volume Ranks 325th in Market Activity - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

Update: TG Therapeutics Shares Fall After Q2 Earnings Miss Expectations - 富途牛牛

Aug 04, 2025
pulisher
Aug 04, 2025

Investor Calendar Invites You to the TG Therapeutics, Inc First Quarter 2016 Earnings Conference Call and Webcast Live on Tuesday May 10, 2016 - ACCESS Newswire

Aug 04, 2025
pulisher
Aug 04, 2025

Why Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 Outlook - Investor's Business Daily

Aug 04, 2025
pulisher
Aug 04, 2025

Health Care Stocks See Gains On Strong Results And Approvals - Finimize

Aug 04, 2025
pulisher
Aug 04, 2025

TG Therapeutics stock falls despite in-line Briumvi sales as BofA reiterates Underperform - Investing.com India

Aug 04, 2025
pulisher
Aug 04, 2025

TG Therapeutics Stock Tumbles 15% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - Stocktwits

Aug 04, 2025
pulisher
Aug 04, 2025

Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results - Benzinga

Aug 04, 2025
pulisher
Aug 04, 2025

TG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis Drug - MSN

Aug 04, 2025
pulisher
Aug 04, 2025

Why Is TG Therapeutics Stock Falling Monday?TG Therapeutics (NASDAQ:TGTX) - Benzinga

Aug 04, 2025

Tg Therapeutics Inc Stock (TGTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):